<DOC>
	<DOCNO>NCT00005613</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy allogeneic autologous peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial compare effectiveness allogeneic stem cell transplantation autologous peripheral stem cell transplantation treat patient non-Hodgkin 's lymphoma Hodgkin 's disease .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Treating Patients With Non-Hodgkin 's Lymphoma Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Compare relapse rate , progression free survival , overall survival patient high risk non-Hodgkin 's lymphoma Hodgkin 's disease treat allogeneic vs autologous stem cell transplantation . II . Compare toxicity ( short long term ) 2 regimens patient . OUTLINE : Cytoreductive therapy : Patients receive 3 course salvage chemotherapy ( e.g. , dexamethasone , high dose cytarabine , cisplatin ( DHAP ) ; etoposide , methylprednisolone , high dose cytarabine , cisplatin ( ESHAP ) ; fludarabine , mitoxantrone , dexamethasone ( FND ) ) . Harvest : Patients HLA identical sibling donor assign allogeneic peripheral blood stem cell ( PBSC ) transplantation group . Patients without HLA identical sibling assign autologous PBSC transplantation group . Allogeneic OR autologous PBSC harvest . Conditioning regimen : Patients receive high dose chemotherapy comprise cyclophosphamide IV 1 hour day -6 -3 carmustine IV 3 hour etoposide IV 3 hour day -6 -4 . PBSC infuse day 0 . Patients follow weekly 3 month , monthly 1 year , annually thereafter . PROJECTED ACCRUAL : A total 120 patient accrue study 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove nonHodgkin 's lymphoma relapse failed achieve complete remission first line induction chemotherapy Intermediate high grade ( include mantle cell , exclude lymphoblastic disease ) No 1 prior salvage chemotherapy regimen , e.g . : Dexamethasone , high dose cytarabine , cisplatin ( DHAP ) Etoposide , methylprednisolone , high dose cytarabine , cisplatin ( ESHAP ) Low grade No 2 prior salvage chemotherapy regimen , e.g . : Fludarabine , mitoxantrone , dexamethasone ( FND ) ESHAP DHAP OR Histologically proven stage III IV Hodgkin 's disease relapse failed achieve remission combination induction chemotherapy Prior primary radiotherapy allow relapse high risk ( e.g. , recurrence radiation field , B symptom , liver/marrow involvement ) No 2 prior salvage chemotherapy regimens Allogeneic stem cell transplantation group : Availability 6 antigen ( A , B , DR locus ) HLA match sibling donor No active CNS disease A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 15 55 Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 3 time normal PT PTT normal Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : LVEF least 45 % MUGA scan echocardiogram No myocardial infarction within past 6 month No arrhythmia unless medically control Pulmonary : FEV1 least 50 % predict DLCO least 50 % predict Other : No diabetes mellitus thyroid disease unless medically control No active serious infection HIV negative Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>